Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Acrivon Therapeutics, Inc. (ACRV) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Acrivon Therapeutics, Inc. is a member of our Medical group, which includes 1047 di ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 Acrivon Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No .) 480 Arsenal Way Suite 100 Watertown, Massachusetts 02472 (Add ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-41551 Acrivon Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Del ...

Investors are always looking for stocks that are poised to beat at earnings season and Acrivon Therapeutics, Inc. (ACRV) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Acrivon Therapeutics is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible ...

•  Initial ACR-368 Phase 2b clinical data in patients with ovarian or endometrial cancers (n=26; 10 OncoSignature-positive and 16 OncoSignature-negative) are being presented•  A 50% confirmed overall response rate observed with ACR-368 in OncoSignature-positive gynecological (ovarian and endometrial) cancers•  Initial clinical validation of AP3 patient selection platform, demonstrated ability to prospectively predict ACR-368 RECIST responders (p-value = 0.0038)•  ACR-2316, a potential first-in-class dual WE ...

Buffett Grabs More of This Stock, Plus Other Notable Insider Buying frender / iStock via Getty Images At the end of the previous week, the Oracle of Omaha yet again boosted his stake in a media giant’s tracking stocks, even with shares still in retreat. Meanwhile, a couple of industrials and a couple of biotechs also saw notable insider purchases made in the past week. Overall, insider buying has slowed.A well-known adage reminds us that corporate insiders and 10% owners really only buy shares of a compan ...

WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced it will be holding a virtual corporate R&D even ...

Acrivon Therapeutics (NASDAQ:ACRV) stock is rocketing higher on Tuesday after the clinical-stage biopharmaceutical company announced a $130 million private placement.This new funding comes from a private investment in public equity (PIPE) with existing and new accredited investors. This has the company selling 8,235,000 shares of ACRV stock for $8.50 per share.The offer also includes pre-funded warrants for 7,060,000 shares being sold for $8.49 each. The exercise price for these warrants is one penny. They ...

WATERTOWN, Mass, April 09, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced that it has entered into a securities purchase a ...

akinbostanci There is a strong case to be made for having a position in small cap stocks at this time. Reasons include: Anticipated Fed easing may lift small caps more than large caps Mean reversion - small caps have underperformed large caps by historic amounts over the past five years A potential slow down or reversal of the rally in tech which has disproportionally benefitted large cap indices such as the S&P 500. Despite this, I recently wrote an article on Seeking Alpha recommending that investors s ...